

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

STATUS OF THE CLAIMS:

Kindly cancel claim 5, 9, 48, and 52 and amend claims 2, 8, 10, 15, 16, 45, 51, 53, 55, 57, and 59.

1. cancelled
2. (currently amended) An isolated polypeptide which has at least one bioactivity of an ACE-2 polypeptide comprising an amino acid sequence having an amino acid identity of at least ~~about~~ 90% with the entire amino acid sequence set forth in SEQ ID NO: 2, wherein at least one of His374, His 378, and His417 are any amino acid other than histidine.
3. (previously presented) The isolated polypeptide of claim 2, which is a mammalian polypeptide.
4. (previously presented) The isolated polypeptide of claim 3, wherein the polypeptide is a human polypeptide.
5. (cancelled)
6. (previously presented) The isolated polypeptide of claim 4, which is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1, with a mutation resulting in a variant where at least one of His374, His 378, and His417 are any amino acid other than histidine.
7. (previously presented) The isolated polypeptide of claim 6, which has the amino acid sequence set forth in SEQ ID NO: 2 with a mutation resulting in a variant where at least one of His374, His 378, and His417 are any amino acid other than histidine.
8. (currently amended) An isolated polypeptide which has at least one bioactivity of an ACE-2 polypeptide comprising an amino acid sequence which is at least ~~about~~ 90% identical to at least ~~about~~ 15 consecutive amino acid residues of SEQ ID NO: 2 wherein at least one of His374, His 378, and His417 are any amino acid other than histidine.
9. (cancelled)
10. (currently amended) The isolated polypeptide of claim 98, which binds an ACE-2 target peptide.
11. (previously presented) The isolated polypeptide of claim 10, which binds angiotensin I.

(Page 2 of 5)

12. (previously presented) The isolated polypeptide of claim 11, which lacks the ability to hydrolyze angiotensin I into angiotensin (1-9).
13. (previously presented) The isolated polypeptide of claim 10, which binds kinetensin.
14. (previously presented) The isolated polypeptide of claim 13, which lacks the ability to hydrolyze kinetensin into kinetensin (1-8).
15. (currently amended) The isolated polypeptide of claim 8, which is encoded by a nucleic acid which hybridizes to a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1 or a complement thereof.
16. (currently amended) An isolated polypeptide which has at least one bioactivity of an ACE-2 polypeptide comprising an amino acid sequence which is at least about 90% similar to at least about 50 consecutive amino acid residues of SEQ ID NO: 2 and which has a bioactivity of an ACE-2 polypeptide, wherein at least one of His374, His 378, and His417 are any amino acid other than histidine.
- 17-43 cancelled.
44. (withdrawn) An antibody which binds the polypeptide of claim 8.
45. (currently amended) An isolated polypeptide which has at least one bioactivity of an ACE-2 polypeptide comprising an amino acid sequence having an amino acid identity of at least about 90% with the entire amino acid sequence set forth in SEQ ID NO: 2, wherein at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.
46. (previously presented) The isolated polypeptide of claim 44, which is a mammalian polypeptide.
47. (previously presented) The isolated polypeptide of claim 45, wherein the polypeptide is a human polypeptide.
48. (cancelled)
49. (previously presented) The isolated polypeptide of claim 47, which is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1, with a mutation resulting in a variant where at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.
50. (previously presented) The isolated polypeptide of claim 47, which has the amino acid sequence set forth in SEQ ID NO: 2 with a mutation resulting in a variant where at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.

51. (currently amended) An isolated polypeptide comprising which has at least one bioactivity of an ACE-2 polypeptide an amino acid sequence which is at least ~~about~~ 90% identical to at least ~~about~~ 15 consecutive amino acid residues of SEQ ID NO: 2 wherein at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.
52. (cancelled)
53. (currently amended) The isolated polypeptide of claim ~~51~~52, which binds an ACE-2 target peptide.
54. (previously presented) The isolated polypeptide of claim 53, which binds angiotensin I.
55. (currently amended) The isolated polypeptide of claim ~~51~~52, which lacks the ability to hydrolyze angiotensin I into angiotensin (1-9).
56. (previously presented) The isolated polypeptide of claim 53, which binds kinetensin.
57. (currently amended) The isolated polypeptide of claim ~~51~~52, which lacks the ability to hydrolyze kinetensin into kinetensin (1-8).
58. (previously presented) The isolated polypeptide of claim 51, which is encoded by a nucleic acid which hybridizes to a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1 or complement thereof.
59. (currently amended) An isolated polypeptide comprising an amino acid sequence which is at least ~~about~~ 90% similar to at least about 50 consecutive amino acid residues of SEQ ID NO: 2 and which has a bioactivity of an ACE-2 polypeptide, wherein at least one of Glu 375, Glu 402, and Glu 406, are any amino acid other than glutamic acid.
60. (withdrawn) An antibody which binds the polypeptide of claim 51.